Fennec Pharmaceuticals Inc.
FENC
Rank in Stocks
#13571
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading... Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Share Price
$10.83
Last synced: 2026-11-09
Market Cap
$379.78M
Change (1 day)
10.40%
Change (1 year)
39.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Fennec Pharmaceuticals Inc. (FENC)
Category
Healthcare
Operating Margin for Fennec Pharmaceuticals Inc. (FENC)
Operating Margin as of November 2026 TTM: -1.96%
According to Fennec Pharmaceuticals Inc.'s latest financial reports, its current operating margin (TTM) is -1.96%. At the end of 2025 the company had an operating margin of -14.22%.
Operating Margin history for Fennec Pharmaceuticals Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1.96% | -86.22% |
| 2025 | -14.22% | -363.33% |
| 2024 | 5.40% | -108.99% |
| 2023 | -60.09% | -95.92% |
| 2022 | -1,471.60% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -10,520.59% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | -100.00% |
| 2001 | -400,900,112.25% | 68.71% |
| 2000 | -237,629,943.17% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -119.69% |
US
|
|
| -149.01% | -23.97% |
US
|
|
| 25.57% | -113.05% |
AU
|
|
| 31.23% | -115.93% |
BE
|
|
| 29.35% | -114.97% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Fennec Pharmaceuticals Inc.'s operating margin
What is Fennec Pharmaceuticals Inc.'s operating margin?
Fennec Pharmaceuticals Inc.'s operating margin is -1.96%, as of Nov 2026.
What was Fennec Pharmaceuticals Inc.'s operating margin in 2025?
In 2025, Fennec Pharmaceuticals Inc.'s operating margin was -14.22%, compared with 5.40% in 2024.
How has Fennec Pharmaceuticals Inc.'s operating margin changed since 2020?
From 2020 to 2025, Fennec Pharmaceuticals Inc.'s operating margin was highest in 2024 (5.40%) and lowest in 2020 (-10,520.59%).
How does Fennec Pharmaceuticals Inc.'s operating margin compare with similar companies?
Fennec Pharmaceuticals Inc.'s operating margin (-1.96%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.